Get the latest news on immunotherapy
January 13, 2020
Influenza Vaccines Triggers Immune System Response in Tumors
January 12, 2020
Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients
January 11, 2020
Early-Stage Leukemia Vaccine Study Reports 80% Survival Rate
January 8, 2020
FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
January 8, 2020
U.S. cancer death rate sees largest yearly drop
January 3, 2020
Tislelizumab-Chemo Combo Induces Durable Responses in Patients with Stomach, Esophagus Cancers, Trial Data Show
December 13, 2019
Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
December 9, 2019
ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma
December 9, 2019
Nivolumab shows promise in ‘wide variety’ of mismatch repair-deficient cancers
December 8, 2019
Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission
December 8, 2019
ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
December 8, 2019
Hyperprogression Halts Study of Nivolumab in Peripheral T-Cell Lymphomas
December 8, 2019
Speeding Access To New And Innovative Cancer Treatments
November 20, 2019
Opdivo/Yervoy combo for melanoma fails in key patient population
November 1, 2019
5-year survival data positive for nivolumab-based regimens in advanced melanoma
November 1, 2019
STING pathway may be key to tumor cell recognition by immune cells
October 29, 2019
ASDS Steering committee develops evidence-based consensus on cSCC staging, workup, treatment
October 28, 2019
Managing Hematological Immune-Related Adverse Events With Immune Checkpoint Inhibitors
October 28, 2019
Nivolumab improves survival in non-small cell lung carcinoma, study results suggest
October 28, 2019
IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer
October 28, 2019
Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds
September 27, 2019
Maeton’s OT101 Gets Rare Pediatric Disease Designation for Childhood Brain Tumor
September 27, 2019
Systemic immune response in squamous cell carcinoma of the head and neck: A comparative concordance index analysis
September 26, 2019
Tasmanian devil research could help tackle immunotherapy resistance
September 26, 2019
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
September 26, 2019
IL-10-based therapy shows promise when used in combination with anti-PD1 agents in lung and RCC
September 26, 2019
Metabolic Imbalance Associated with Resistance to Checkpoint Inhibitor Nivolumab
September 26, 2019
Boost in Survival Rates for Younger Patients With Melanoma Attributed to Immunotherapy Agents
September 4, 2019
Nivolumab more effective versus investigator’s choice in younger vs older patients with recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
September 4, 2019
TGF-Beta may be a predictive biomarker for response to pembrolizumab in HCC
September 3, 2019
Pooled Analysis Shows Triple OS with Nivolumab in Advanced NSCLC
August 30, 2019
Myasthenia gravis induced by avelumab
August 22, 2019
Anti-TNF therapy given concurrently with ICI therapy may be beneficial in patients with GI irAEs
August 16, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled, phase 3 trial
August 16, 2019
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma
August 16, 2019
ADXS-NEO Provoked Strong Immune Response in Advanced Cancer Patient, Early Trial Data Show
August 14, 2019
ICIs may trigger rare form of bullous pemphigoid
July 27, 2019
Wealth of Immunotherapy Combinations Places Emphasis on Biomarkers for NSCLC
July 26, 2019
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
July 25, 2019
Update on Frontline Nivolumab/Ipilimumab Combo Demonstrates Positive OS Results in PD-L1+ NSCLC
July 19, 2019
Prophylactic anti-TNF Therapy Improves Safety of Immunotherapies, Mouse Study Says
July 12, 2019
Libtayo Approved in Europe to Treat Metastatic or Advanced Cutaneous Squamous Cell Carcinoma
July 10, 2019
Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors
June 19, 2019
Implementation of a Multidisciplinary Approach for Managing Immunotherapy-Related Toxicities
June 18, 2019
Colorectal Cancer Vaccine Candidate Induces Potent Immune Responses, Interim Trial Results Show
June 18, 2019
Phase 1 Study Demonstrates Safety of Pembrolizumab in Patients With HIV and Advanced Cancer
June 18, 2019
Keytruda approved for metastatic small cell lung cancer that has progressed after previous treatment
June 4, 2019
Alternate Doses of Ipilimumab Show Similar Results in Advanced Melanoma
May 27, 2019
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
May 22, 2019
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
May 17, 2019
Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma
May 16, 2019
First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals
May 16, 2019
Immunotherapy response differs by EFGR mutation subtype
May 16, 2019
FDA approves Bavencio with Inlyta for patients with advanced renal cell carcinoma
May 14, 2019
Adopted cell transfer therapy being studied in sarcoma
May 2, 2019
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
May 1, 2019
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
April 30, 2019
Keytruda-Inlyta combo approved by FDA for untreated advanced kidney cancer
April 22, 2019
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
April 16, 2019
Clinical Trial in Ireland Investigates Cellular Immunotherapy as Treatment for Two Autoimmune Liver Diseases
April 15, 2019
The Gut Microbiome & Cancer Immunotherapy
April 15, 2019
Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma
April 15, 2019
Cancers ‘change spots’ to avoid immunotherapy
April 12, 2019
TKI-Immunotherapy Combinations Push the Envelope in Frontline RCC
April 11, 2019
First Off-the-Shelf Immunotherapy Clinical Trial Launched
April 11, 2019
FDA Expands Keytruda Indication for First-Line Treatment of Non-Small Cell Lung Cancer
April 10, 2019
Comorbidities Result in Fewer Patients in Clinical Trials
April 10, 2019
Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
April 10, 2019
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
April 9, 2019
Incysus Therapeutics gets FDA approval for brain cancer treatment trial
April 9, 2019
SWOG cancer research network study opens window into immune microenviroment
April 9, 2019
The changing landscape of diagnostic biomarkers: Exploring the one-biomarker-per-drug paradigm in oncology
April 8, 2019
Cancer ‘vaccine’ shows promise in human trial of lymphoma patients
April 8, 2019
Clinical Trial Investigates Orbsen Therapeutics’ ORBCEL-C™ Immunotherapy as Treatment for Two Autoimmune Liver Diseases
April 7, 2019
Researchers Develop “Swiss Army Knife” Immunotherapy to “Kick and Kill” HIV
April 5, 2019
Fecal transplants could help patients on cancer immunotherapy drugs
April 2, 2019
Gut microbes can spur immune system to attack cancer
April 1, 2019
UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells
April 1, 2019
Despite research boom, few immunotherapy studies targeting pancreatic cancer
April 1, 2019
How immune cells help tumors escape body’s defenses
March 31, 2019
AACR 2019 Research Roundup: Pancreatic Cancer Immunotherapy, Prostate Cancer Drug Resistance, Insight into Inherited Cancer Mutations
March 30, 2019
ETH researchers take major step towards personalized cancer immunotherapy
March 29, 2019
Combining DNA Damage Response Inhibitors with Immunotherapy Boosts SCLC Clearance, Mouse Study Shows
March 29, 2019
Immunotherapy for Pre-Cancerous Lesions May Reduce Skin Cancer Risk Over Time
March 28, 2019
Harnessing T-cell “stemness” could enhance cancer immunotherapy
March 28, 2019
Better Muscle Mass Linked to Improved Immunotherapy Response
March 28, 2019
New study confirms EpCAM as promising target for cancer immunotherapy
March 24, 2019
Bladder Cancer Guidelines Showcase Advent of Immunotherapy
March 22, 2019
FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC
March 21, 2019
Immunotherapies for Staphylococcus aureus
March 21, 2019
Imugene gains guidance for KEY-Vaxx Immunotherapy development
March 21, 2019
New U.K. Partnership Aims To Improve Access Immunotherapy For Cancer Patients
March 21, 2019
OHSU Knight Cancer Institute Throws Out Old System Of Clinical Trials
March 20, 2019
EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC
March 18, 2019
Immunotherapy Approved for Triple-Negative Breast Cancer
March 18, 2019
Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy
March 15, 2019
TC BioPharm, Trinity College Dublin Pair to Develop Cancer-fighting Cell Therapy
March 13, 2019
Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway
March 13, 2019
Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals
March 12, 2019
Harness the immune system to fight colon cancer
March 11, 2019
FDA Approves Tecentriq-Abraxane Combo as First Immunotherapy Regimen for Breast Cancer
March 11, 2019
Unique Immunotherapy Combinations Provide an Optimistic Outlook in Early Urothelial Carcinoma Trials
March 8, 2019
Precision drugs could unmask cancers to immune system and boost effects of immunotherapy
March 8, 2019
FDA approves 1st immunotherapy drug to treat breast cancer
March 8, 2019
Immunotherapy in Bladder Cancer
March 8, 2019
More News! Targeting tuberculosis, light-activated drugs, cancer immunotherapies and more
March 8, 2019
Recognizing Endometrial Tumor Immune Features Is Key to Treatment Success
February 26, 2019
Patient-Reported Side Effects: A Crucial Part of Cancer Clinical Trials
February 26, 2019
A Growing Focus on Rare Cancers in Phase I Trials
February 26, 2019
Expert Addresses Toxicity Management for Approved CAR T-Cell Therapies
February 21, 2019
A New Treatment in Oral Immunotherapy Can Relieve Food Allergies, But Few Doctors Offer It
February 21, 2019
Merck in $300M Immune Design boost to Keytruda
February 19, 2019
Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
February 13, 2019
Keytruda combo outshines Opdivo in kidney cancer
February 13, 2019
Positive Results Reported in Phase 1 Trial of Bavencio for Malignant Mesothelioma
February 13, 2019
Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma
February 12, 2019
Tuberculosis—Inhibiting host cell death with immunotherapy
February 12, 2019
Bavencio Shows Promise in Phase 1 Trial of Heavily Treated Malignant Mesothelioma Patients
February 12, 2019
Merck and Pfizer combination therapy improves kidney cancer survival
February 11, 2019
Merck Drug Found to Extend Lives of Brain-Cancer Patients
February 11, 2019
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
February 8, 2019
GE Healthcare, Vanderbilt University Medical Center to Develop Apps that Predict Immunotherapy Responses
February 7, 2019
Immunotherapy appears better than chemotherapy for aggressive type of skin cancer
February 6, 2019
FDA Expands Alimta’s Label for Initial Treatment of Metastatic Lung Cancer
February 5, 2019
Phase 1b Trial of ADCT-301 in Advanced Solid Tumors Doses First Patient
February 4, 2019
Emerging Immunotherapy Approaches For Urothelial Cancer
February 1, 2019
Tumors with More Mutations Respond Better to Immunotherapy, Study Suggests
January 31, 2019
FDA Expands Alimta Approval for Use With Immunotherapy and Chemo in Lung Cancer
January 31, 2019
Lung-MAP Trial Opens Enrollment to Patients With All Types of NSCLC
January 29, 2019
Brahmer Highlights Immunotherapies in the Pipeline for NSCLC
January 29, 2019
Could an immunotherapy treatment from Israel cure cancer?
January 29, 2019
Clinical trials offer opportunity for breakthroughs in cancer treatment; increased participation is key
January 29, 2019
CAR T Cells Get an Invisibility Cloak
January 28, 2019
Blocking pro-fibrosis pathway may improve immunotherapy of metastatic breast cancer
January 25, 2019
Immunotherapy Drug Avelumab Could Extend Survival for Patients with Unresectable Mesothelioma
January 24, 2019
Ongoing Study Looks to Bring Immunotherapy to Presurgical Setting in HCC
January 17, 2019
Mesothelioma Researchers Seek More Effectiveness from Immunotherapy
1/11/2019
VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
1/11/2019
Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer
1/9/2019
Phase 3 Trial Explores Cabometyx-Tecentriq Combo Therapy in Advanced Liver Cancer
1/9/2019
FDA OKs Phase 2 Trial of AE37-Keytruda Combo in Metastatic Triple-negative Breast Cancer
1/9/2019
Does the Cost Outweigh the Benefit for CAR T-Cell Therapy?
1/9/2019
New clinical trial highlights haNK cell therapy in combination with IL-15 superagonist N-803 and avelumab
1/8/2019
Immune to cancer’s return? The day could be coming
1/7/2019
AVID200, which reverses immunosuppression to enhance sensitivity to checkpoint blockade, enters phase I trial
12/20/2018
AZ/Merck & Co get new US use for ovarian cancer drug
12/19/2018
Advanced melanoma trial when Keytruda alone is not enough
12/19/2018
Keytruda Seen as ‘Kinder’ and Superior to Standard Therapies for Advanced Head and Neck Cancer Patients in Phase 3 Trial
12/18/2018
Researchers identify ways breast cancer avoids immune system detection
12/18/2018
Metal chemotherapy drugs boost the impact of immunotherapy in cancer
12/18/2018
Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients
12/14/2018
AMG 330 Immunotherapy Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia
12/6/2018
FDA approves Genentech drug for lung cancer
11/27/2018
Generex Biotechnology Signs Clinical Trial Agreement with the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer
11/27/2018
Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data Shows
11/26/2018
Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of First-Line Chemotherapy
11/26/2018
Nivolumab/Ipilimumab Combo Misses Primary Endpoint in Phase III SCLC Trial
11/26/2018
Avelumab Fails to Meet Primary Endpoints in Phase III Ovarian Cancer Trial
11/25/2018
Combos Pairing Inhibitors of Angiogenesis and Immune Checkpoints Have Potential
11/21/2018
Durable Responses Seen With Atezolizumab in Advanced Alveolar Soft Part Sarcoma
11/6/2018
CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
11/5/2018
Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma
10/18/2018
Antiangiogenics and Immunotherapy Combos Show Promising Activity in Solid Tumors
10/17/2018
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
10/05/2018
MEDI0457 with Anti-PD-1 Therapy Shows Promise in Treating HPV-associated Head and Neck Cancer
10/04/2018
Immunotherapy Pioneers Win Nobel Prize for Research on Checkpoint Inhibitors
10/01/2018
Case study shows metastatic urothelial carcinoma patient with gastritis infection after receiving atezolizumab then
09/28/2018
FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
10/24/2017